retatrutide phase 3 trial results VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide yields results similar to
Description
(Kailera Therapeutics) and @Deepa Nagpal (SygnifyQ) to explore the evolving science and operations behind GLP-1 agonists, from peptide manufacturing innovation to supply chain resilience, purity assays, and technology transfer for scalable growth
The fat percentage is lower than traditional keto because protein is taking up a larger share of total calories
55% of GLP-1 users believe there are cities or countries that now feel more accessible because of their improved confidence or mobility
It is worth noting that the landscape for licensed weight-management medicines in the UK is evolving
2022 Dec;118(6):11501158
If optimization and value are your priorities, build your own stack
